The Bay Area's biotech industry faced significant challenges in 2024, with economic output taking a double-digit hit.

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

Tech The Bang & Olufsen-powered Spaceshop enables Vollebak to boldly go into the future of retail Cult clothing brand Vollebak reaches for the stars with this cross-disciplinary take on the ...

Krystal Biotech's phase 3 trial, IOLITE, evaluates KB803 for corneal abrasions in DEB patients, targeting the disease at a molecular level. The trial involves 16 patients, aged six months or older, in ...

Discover the latest developments in the neuroplastogens field, including Elkedonia’s funding to address neuropsychiatric disorders.

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, ...

With partners like The Metropolitan Museum of Art, Musée d’Orsay, and Art Basel, Samsung Art TVs reimagine the screen as a refined canvas that enhances – rather than disrupts – your home’s interior ...

Durham-based GeneCentric Therapeutics, a cancer diagnostics company, has closed on an $8 million round of venture capital to launch and commercialize a novel liquid biopsy platform for guiding ...

The Biotechnology Master of Science degree program provides students with advanced coursework in biotechnical and biomolecular sciences. Graduates are prepared for positions in research, and ...

Across the recent three months, 7 analysts have shared their insights on Krystal Biotech (NASDAQ:KRYS), expressing a variety of opinions spanning from bullish to bearish. The following table ...

(The Center Square) - The “bioindustrial revolution” is coming. Pennsylvania lawmakers want the commonwealth to be at its forefront. Gov. Josh Shapiro has made the biotech industry a core focus of his ...

By Dean Seal Shares of Sana Biotechnology jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes.